Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 62-69

  Chen, Zhi Kui ^a   Cai, Min Xian ^b   Yang, Jing ^a   Lin, Li Wu ^a   Xue, En Sheng ^a   Huang, Jing ^c   Wei, Hong Fen ^c   Zhang, Xiu Juan ^c   Ke, Li Ming ^c  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Second Hospital of Longyan City   (China)

^c Ultrasonic Medicine Institute of Fujian Province   (China)

Author keywords

Angiogenesis; Docetaxel; Hepatocellular carcinoma; Interstitial chemotherapy; Sustained release

Indexed keywords

DOCETAXEL; MICROSPHERE; POLYGLACTIN;

ANGIOGENESIS; ANGIOPOIETIN 2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RELEASE; FEMALE; FIBROBLAST GROWTH FACTOR 2 GENE; GENE; GENE SEQUENCE; HISTOPATHOLOGY; LD 50; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; TUMOR GROWTH; VASCULOTROPIN GENE; XENOGRAFT;

ANGIOPOIETIN-2; ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HUMANS; LACTIC ACID; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICROSPHERES; NEOVASCULARIZATION, PATHOLOGIC; POLYGLYCOLIC ACID; REAL-TIME POLYMERASE CHAIN REACTION; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864037653     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9762-2     Document Type: Article

References (46)

1. Cha C, DeMatteo RP, Blumgart LH. Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35 (5 Suppl 2):S130-7. (Pubitemid 35278650)
2. Curley SA, Izzo F, Ellis LM, Nicolas VJ, Vallone P. Radiofre-quency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232(3):381-91.
3. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-85. (Pubitemid 29488770)
4. Marin-Hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. Crit Rev Oncol Hematol. 2003;47(1):13-27. (Pubitemid 36802322)
5. Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol. 2007;81(2):201-8. (Pubitemid 44963980)
6. Wowra B, Mentrup E, Zeller WJ, Stricker H, Sturm V. CT kinetics of intratumor liposome deposits. Onkologie. 1988;11(2): 81-4.
7. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg. 1995;83(6):1029-37. (Pubitemid 26048143)
8. Lee KS, Ro J, Nam BH, Lee ES, Kwon Y, Kwon HS. et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat. 2008;109(3):481-9. (Pubitemid 351692059)
9. Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008;110(3):531-9. (Pubitemid 351962591)
10. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54(5):1089-94.
11. Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008;283(30):20635-44.
12. Ho K, Slevin N. A comparison of cisplatin and fluorouracil alone or with docetaxel in squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol. 2008;5(6):306-7. (Pubitemid 351780944)
13. Sculier JP, Moro-Sibilot D. First-and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J. 2009;33(4): 915-30.
14. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226-32.
15. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10): 2643-55.
16. Zhang Y, Sophocleous AM, Schwendeman SP. Inhibition of peptide acylation in PLGA microspheres with water-soluble divalent cationic salts. Pharm Res. 2009;26(8):1986-94.
17. Ranganath SH, Kee I, Krantz WB, Chow PK, Wang CH. Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharm Res. 2009;26(9):2101-14.
18. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angio-genesis and metastasis\correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
19. Homayoun P, Mandal T, Landry D, Komiskey H. Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres. J Pharm Pharmacol. 2003;55(7):933-8. (Pubitemid 36916683)
20. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6.
21. Holmgren L, O'Reilly MS, Folkman J. Dormancy of microme-tastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1(2):149-53.
22. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of anti-angiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94(12):883-93. (Pubitemid 34778087)
23. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57(1): 81-6. (Pubitemid 27021522)
24. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangio-genic activity. Clin Cancer Res. 1996;2(11):1843-9. (Pubitemid 26384151)
25. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized trans-genic breast cancer. Cancer Biother Radiopharm. 1999;14(1):31-6. (Pubitemid 29157732)
26. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is syn-ergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61(8):3369-72. (Pubitemid 32695027)
27. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 2002;1(13):1191-200.
28. De Jong JS, van Diest PJ, Baak JPA. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology. 2000;36(4): 306-12. (Pubitemid 30198912)
29. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res. 1997;57(6):1043-6. (Pubitemid 27138597)
30. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147(1):33-41.
31. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143(2):401-9. (Pubitemid 24058195)
32. Schneider M, Arditi M, Barrau MB, Brochot J, Broillet A, Ventrone R, et al. BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles. Invest Radiol. 1995;30(8):451-7.
33. Schneider M. Sonovue, a new ultrasound contrast agent. Eur Radiol. 1999;9(Suppl 3):S347-8.
34. Sidhu PS, Allan PL, Cattin F, Cosgrove DO, Davies AH, Do DD, et al. Diagnostic efficacy of SonoVue, a second generation contrast agent, in the assessment of extracranial carotid or peripheral arteries using colour and spectral Doppler ultrasound: a multi-centre study. Br J Radiol. 2006;79(937):44-51. (Pubitemid 43159315)
35. Ricci P, Laghi A, Cantisani V, Paolantonio P, Pacella S, Pagliara E, et al. Contrast-enhanced sonography with SonoVue: enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol. 2005;184(3):821-7. (Pubitemid 43899507)
36. Schneider M. SonoVue, a new ultrasound contrast agent. Eur Radiol. 1999;9(Suppl 3):S347-8.
37. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia-and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther. 2006;5(5):1227-38. (Pubitemid 43881315)
38. Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang VP, Soong T, et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006; 12(9):2706-15.
39. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol. 2004;286(6):L1194-201. (Pubitemid 38656655)
40. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92((9 Suppl)):II365-71.
41. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993;69(5): 508-17. (Pubitemid 24004487)
42. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189(2):824-31. (Pubitemid 23032448)
43. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands Jr. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest. 1999;103(3): 341-5. (Pubitemid 29069983)
44. Ahmad SA, Liu W, Jung YD, Fan F, Reinmuth N, Bucana CD, et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer. 2001;92(5):1138-43. (Pubitemid 32861662)
45. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001;61(5):2145-53. (Pubitemid 32692040)
46. White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA. 2003;100(9):5028-33. (Pubitemid 36542652)